Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Automotive & E-Mobility

SES AI Shares Face Critical Test as Quarterly Results Loom

Robert Sasse by Robert Sasse
November 3, 2025
in Automotive & E-Mobility, Earnings, Penny Stocks, Trading & Momentum
0
SES AI Stock
0
SHARES
38
VIEWS
Share on FacebookShare on Twitter

SES AI shares are displaying significant volatility ahead of Wednesday’s crucial quarterly earnings release. The overall market sentiment remains tense, fueled by a dramatic surge in short interest and conflicting signals emerging from the company’s recent activities.

Market Performance Under Scrutiny

The stock enjoyed a substantial 10.80% rally on Friday, closing at $2.36 after reaching an intraday peak of $2.40. However, this single-day surge belies a broader downward trend, with the equity having shed 23.13% of its value over the preceding ten trading sessions. Market projections indicate an opening price of $2.30 for Monday’s trading session.

Short Sellers Circle

A particularly concerning development for bullish investors is the explosive growth in short positions. Data through October 15 reveals that the number of shares sold short skyrocketed by 62%, reaching 8.13 million. This represents 3.7% of all outstanding shares being held in short positions, indicating substantial market skepticism about the company’s near-term prospects.

Wall Street’s Cautious Stance

Financial analysts maintain a guarded outlook on SES AI:

Should investors sell immediately? Or is it worth buying SES AI?

  • The consensus rating stands at “Hold”
  • The average price target is set at $2.00, reflecting a 15% discount to current trading levels
  • Analyst recommendations show division, with one “Buy” rating countered by a “Sell” recommendation

Further compounding concerns, corporate insiders have demonstrated limited confidence through significant share sales. Meanwhile, institutional investors maintain positions representing approximately 30% of the company’s equity.

All Eyes on Wednesday’s Report

The upcoming Q3 earnings announcement, scheduled for after market close on Wednesday, represents a pivotal moment for SES AI. Market expectations are clearly established, with analysts forecasting a per-share loss of $0.03. The central question remains whether the company can surpass these projections or if it will validate the pessimistic outlook held by short sellers.

The forthcoming earnings release will likely determine the stock’s directional momentum in the weeks ahead, answering whether SES AI can stage a meaningful recovery or confirm the bearish sentiment currently dominating trading activity.

Ad

SES AI Stock: Buy or Sell?! New SES AI Analysis from February 8 delivers the answer:

The latest SES AI figures speak for themselves: Urgent action needed for SES AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

SES AI: Buy or sell? Read more here...

Tags: SES AI
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Newell Brands Stock

Newell Brands Shares Plummet Following Disappointing Earnings Report

Kura Oncology Stock

Pivotal Week Ahead for Kura Oncology Investors

Wabtec Stock

Wabtec Shares Poised for Growth on Strong Quarterly Performance

Recommended

Technology Cloud computing

Unusual Options Activity in Micron Technology A Split Sentiment Among Investors

2 years ago

Gold’s Precarious Rebound: A Temporary Respite or Bear Trap?

3 months ago
Finances-and-tech

Analyst Evaluations and Price Targets for DocGo NASDAQ DCGO

2 years ago
Upland Software Stock

Upland Software Shares Tumble Despite Strong Earnings Beat

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Trending

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

by SiterGedge
February 8, 2026
0

Biotechnology firm Quanterix has taken a pivotal step toward transforming the diagnosis of Alzheimer's disease. The company...

Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com